5don MSN
Novo Nordisk’s New Weight Loss Shot Loses To Rival Eli Lilly In Clinical Trial—Stock Plummets
Novo’s CagriSema shot was shown to be less effective than rival Lilly’s tirzepatide ...
Reuters on MSN
Novo Nordisk to halve US list price of Wegovy from 2027
Novo Nordisk will slash U.S. list prices of its blockbuster diabetes and weight-loss drugs Ozempic and Wegovy by up to 50% starting next year, the Danish drugmaker said on Tuesday. Ciara Lee reports.
Battling to regain its market share over rival Eli Lilly, Novo Nordisk announced Tuesday that it will reduce the list prices of its popular weight loss drug Wegovy and diabetes drugs Ozempic and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results